Ever­est climbs clos­er to Covid-19 boost­er mar­ket; A French up­start snags funds to find drugs

Ever­est Med­i­cines said its Covid-19 mes­sen­ger RNA part­ner passed a mid-stage test in­ves­ti­gat­ing its vac­cine against Pfiz­er and BioN­Tech’s Comir­naty.

Prov­i­dence Ther­a­peu­tics’ PTX-COVID19-B was non-in­fe­ri­or to the Big Phar­ma’s shot in a Phase II tri­al com­par­ing the vac­cines in 18- to 64-year-olds in Cana­da and South Africa, Ever­est dis­closed Wednes­day. The shot was test­ed as a two-jab in­tra­mus­cu­lar in­jec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.